Vascular by Design.
Human by Nature.
Future of drug development
Elevate your preclinical drug development with our 3D bioprinted vascularized human tissue models.
Vascular by Design.
Human by Nature.
Future of drug development
Elevate your preclinical drug development with our 3D bioprinted vascularized human tissue models.
Vascular by Design.
Human by Nature.
Future of drug development
Elevate your preclinical drug development with our 3D bioprinted vascularized human tissue models.
Redefining drug development.
Replicating human tissues.
VoxCell empowers scientists and drug developers to study drug behavior with unprecedented physiological relevance.
Vascular complexity
Vascular complexity is the core of our innovation
We deliver human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. Committed to innovation and excellence, VoxCell continues to expand its impact on a global scale.
Human biology, not animal biology
Join us at the forefront of a global shift
As regulators and industry leaders embrace New Approach Methodologies (NAMs), VoxCell’s technology delivers the complexity and predictive power needed to evaluate drug response, safety, and efficacy, reducing reliance on animals while accelerating the development of more effective therapies.
Vascular complexity
Vascular complexity is the core of our innovation
We deliver human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. Committed to innovation and excellence, VoxCell continues to expand its impact on a global scale.
Human biology, not animal biology
Join us at the forefront of a global shift
As regulators and industry leaders embrace New Approach Methodologies (NAMs), VoxCell’s technology delivers the complexity and predictive power needed to evaluate drug response, safety, and efficacy, reducing reliance on animals while accelerating the development of more effective therapies.
Physiologically relevant perfusion
Complex tissue models
3D vascularized issue models for preclinical screening. From efficacy to safety, including vascular toxicity. Can be customized to match your requirements for your pipeline. Our tissues allow long term and multi-dose studies (80%+ for up to 21 days*).
Vascular complexity
The core of our innovation
Human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. VoxCell continues to expand its impact on a global scale.
Human biology, not animal biology
Join us at the forefront of a global shift
As regulators and industry leaders embrace New Approach Methodologies (NAMs), VoxCell’s technology delivers the complexity and predictive power needed to evaluate drug response, safety, and efficacy, reducing reliance on animals while accelerating the development of more effective therapies.
Physiologically relevant perfusion
Complex tissue models
3D vascularized issue models for preclinical screening. From efficacy to safety, including vascular toxicity. Can be customized to match your requirements for your pipeline. Our tissues allow long term and multi-dose studies (80%+ for up to 21 days*).
Physiologically relevant perfusion
Complex tissue models
3D vascularized issue models for preclinical screening. From efficacy to safety, including vascular toxicity. Can be customized to match your requirements for your pipeline. Our tissues allow long term and multi-dose studies (80%+ for up to 21 days*).
Predictive models in preclinical development.
Unlocking the Power of Perfusion
Better understand your pipeline before clinical trials.
Drug Efficacy & Safety
Drug Efficacy & Safety
Drug Efficacy & Safety
Therapeutic Index Determination
Therapeutic Index Determination
Therapeutic Index Determination
Morphological and Structural Analysis
Morphological and Structural Analysis
Morphological and Structural Analysis
Drug Combination Tests
Drug Combination Tests
Drug Combination Tests
our workflow
our workflow
our workflow
Flow, integrity, permeability
Matching specific requirements, ensuring optimal performance for drug screening.
Physiologically relevant
Physiologically relevant
Physiologically relevant
Highly reproducible
Highly reproducible
Highly reproducible
Customizable dimensions and vasculature
Customizable dimensions and vasculature
Customizable dimensions and vasculature
Multicellular structures
Multicellular structures
Multicellular structures
3D capillary vessels
3D capillary vessels
3D capillary vessels
Unidirectional flow
Unidirectional flow
Unidirectional flow
Innovation in tissue models.
Partners in health.
Gold Nanoparticle Extravasation
In partnership with BC Cancer. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
In partnership with BC Cancer. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
T cell engagers.
In partnership with TheryCell. Extravasation and Efficacy of T cell in Patient-derived NSCLC.
COMMENCED 2024
A new generation of TNBC tissue models.
In partnership with Inaphea. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with UVic. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
Non-oncology Ocular indications.
Workplan in progress.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with ValiRx. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with NMI. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
T cell engagers.
In partnership with TheryCell. Extravasation and Efficacy of T cell in Patient-derived NSCLC.
COMMENCED 2024
A new generation of TNBC tissue models.
In partnership with Inaphea. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with Uvic. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
In partnership with UVic. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
Non-oncology Ocular indications.
Workplan in progress.
2025/2026
Workplan in progress.
2025/2026
A new generation of TNBC tissue models.
In partnership with ValiRx. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
In partnership with ValiRx. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
T cell engagers.
In partnership with NMI. Extravasation and Efficacy of T cell in Patient-derived NSCLC.
COMMENCED 2024
In partnership with NMI. Extravasation and Efficacy of of T cell in Patient-derived NSCLC.
COMMENCED 2024
Gold Nanoparticle Extravasation
In partnership with BC Cancer. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
T cell engagers.
In partnership with TheryCell. Extravasation and Efficacy of T cell in Patient-derived NSCLC.
COMMENCED 2024
A new generation of TNBC tissue models.
In partnership with Inaphea. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with UVic. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
Non-oncology Ocular indications.
Workplan in progress.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with ValiRx. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with NMI. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
T cell engagers.
In partnership with TheryCell. Extravasation and Efficacy of T cell in Patient-derived NSCLC.
COMMENCED 2024
A new generation of TNBC tissue models.
In partnership with Inaphea. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
Gold Nanoparticle Extravasation
In partnership with Uvic. Therapy Enhancement in TNBC Tissue Models.
COMMENCED 2025
Non-oncology Ocular indications.
Workplan in progress.
2025/2026
A new generation of TNBC tissue models.
In partnership with ValiRx. Evolution of breast cancer models using PDCs from their biobank.
COMMENCED 2025
T cell engagers.
In partnership with NMI. Extravasation and Efficacy of T cell in Patient-derived NSCLC.
COMMENCED 2024
Built layer by layer
to suit your needs.
01
Custom vascularization software
We generate customizable tissue with 3D vasculature based on physiological parameters. Select vasculature, tissue size, density, and characteristics.
01
Custom vascularization software
We generate customizable tissue with 3D vasculature based on physiological parameters. Select vasculature, tissue size, density, and characteristics.
01
Custom vascularization software
We generate customizable tissue with 3D vasculature based on physiological parameters. Select vasculature, tissue size, density, and characteristics.
02
Proprietary bioinks
Biocompatible polymers loaded with living cells, replicating the natural ECM of tissues. Mimics native tissue, highly biocompatible, stable, and reliable.
02
Proprietary bioinks
Biocompatible polymers loaded with living cells, replicating the natural ECM of tissues. Mimics native tissue, highly biocompatible, stable, and reliable.
02
Proprietary bioinks
Biocompatible polymers loaded with living cells, replicating the natural ECM of tissues. Mimics native tissue, highly biocompatible, stable, and reliable.
03
High resolution bioprinting
Light-based bioprinting resulting in submicron resolution. Fabrication flexibility, suitable for a wide range of material compatibility.
03
High resolution bioprinting
Light-based bioprinting resulting in submicron resolution. Fabrication flexibility, suitable for a wide range of material compatibility.
03
High resolution bioprinting
Light-based bioprinting resulting in submicron resolution. Fabrication flexibility, suitable for a wide range of material compatibility.